Overview

TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome

Status:
Completed
Trial end date:
2019-04-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the cutaneous toxicity and treatment response associated with administering concurrent TSEB and brentuximab vedotin in patients with mycosis fungoides or Sézary Syndrome.
Phase:
Phase 1
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborators:
Seagen Inc.
Seattle Genetics, Inc.
Treatments:
Antibodies, Monoclonal
Brentuximab Vedotin